Synbiotic Supplementation Improves Metabolic Factors and Obesity Values in Women with Polycystic Ovary Syndrome Independent of Affecting Apelin Levels: A Randomized Double-Blind Placebo-Controlled Clinical Trial

Document Type : Original Article


1 Student’s Research Committee, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran

2 Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran

3 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

4 Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran

5 Department of Obstetrics and Gynecology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran


Background: This research investigated the symbiotic supplement influences on serum glycemic indices and lipids
as well as apelin rates and obesity values in polycystic ovary syndrome (PCOS) patients.

Materials and Methods: A total of 68 obese or overweight patients (20-44 years old) with PCOS were enrolled to
conduct a randomized double-blinded placebo-controlled clinical trial. A total of 34 people in the synbiotic group received
a synbiotic supplement and 34 people in the placebo group received placebo, daily for 8 weeks. Fasting blood
specimens, anthropometric measurements and dietary intake data were gathered three times during the study. The
information was analyzed by independent t test, paired t test, analysis of covariance and chi-square test.

Results: Synbiotic supplementation significantly decreased serum fasting glucose (P=0.02), insulin (P=0.001), homeostatic
model assessment for insulin resistance (IR, P=0.001), weight (P=0.02), body mass index (BMI, P=0.02),
waist circumference (WC, P=0.01), hip circumference (HC, P=0.02), and waist-to-height ratio (WHtR, P=0.02) but
significantly increased high-density lipoprotein (HDL) cholesterol (P=0.02) compared to the placebo. At the end of the
trial, no significant differences were seen in serum total cholesterol, triglyceride (TG), low-density lipoprotein (LDL)
cholesterol, or apelin levels as well as waist-to-hip ratio (WHR) between the two groups.

Conclusion: Synbiotic supplementation improved glycemic indices, lipid profile and obesity values in women
with PCOS. These beneficial effects were not related with alterations in serum apelin levels (Registration number:


1.Karakas SE. New biomarkers for diagnosis and management ofpolycystic ovary syndrome. Clin Chim Acta. 2017; 471: 248-253.
2.De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G,Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14(1): 38.
3.Zhang J, Sun Z, Jiang S, Bai X, Ma C, Peng Q, et al. Probioticbifidobacterium lactis v9 regulates the secretion of sex hormonesin polycystic ovary syndrome patients through the gut-brain axis.Systems. 2019; 4(2): e00017-19.
4.Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or withoutpolycystic ovary syndrome, display altered inositols metabolism.Hum Reprod. 2008; 23(6): 1439-1446.
5.Yousuf SD, Rashid F, Mattoo T, Shekhar C, Mudassar S, Zargar MA, et al. Does the oral contraceptive pill increase plasma intercellularadhesion molecule-1, monocyte chemoattractant protein-1, andtumor necrosis factor-α levels in women with polycystic ovarysyndrome: a pilot study. J Pediatr Adolesc Gynecol. 2017; 30(1):58-62.
6.Butterworth J, Deguara J, Borg CM. Bariatric surgery, polycysticovary syndrome, and infertility. J Obes. 2016; 2016: 1871594.
7.Nambiar V, Vijesh VV, Lakshmanan P, Sukumaran S, SuganthiR.Association of adiponectin and resistin gene polymorphisms inSouth Indian women with polycystic ovary syndrome. Eur J ObstetGynecol Reprod Biol. 2016; 200: 82-88.
8.Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D,et al. Obesity, type 2 diabetes mellitus and cardiovascular diseaserisk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016; 207: 214-219.
9.Ma WY, Yu TY, Wei JN, Hung CS, Lin MS, Liao YJ, et al. Plasmaapelin: a novel biomarker for predicting diabetes. Clin Chim Acta.2014; 435: 18-23.
10.Fasshauer M, Blüher M. Adipokines in health and disease. TrendsPharmacol Sci. 2015; 36(7): 461-470.
11.Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, et al.Apelin and APJ regulation in adipose tissue and skeletal muscle oftype 2 diabetic mice and humans. Am J Physiol Endocrinol Metab.2010; 298(6): E1161-E1169.
12.Yue P, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298(1): E59-E67.
13.Benk Silfeler D, Gokce C, Keskin Kurt R, Yilmaz Atilgan N, OzturkOH, Turhan E, et al. Does polycystic ovary syndrome itself haveadditional effect on apelin levels? Obstet Gynecol Int. 2014; 2014:536896.
14.Roche J, Ramé C, Reverchon M, Mellouk N, Cornuau M, Guerif F,et al. Apelin (APLN) and apelin receptor (APLNR) in human ovary:expression, signaling, and regulation of steroidogenesis in primaryhuman luteinized granulosa cells. Biol Reprod. 2016; 95(5): 104.
15.Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)–anovel theory for the development of polycystic ovarian syndrome.Med Hypotheses. 2012; 79(1): 104-112.
16.Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, GilA.Effects of probiotics and synbiotics on obesity, insulin resistancesyndrome, type 2 diabetes and non-alcoholic fatty liver disease: areview of human clinical trials. Int J Mol Sci. 2016; 17(6): 928.
17.Yoo JY, Kim SS. Probiotics and prebiotics: present status andfuture perspectives on metabolic disorders. Nutrients. 2016; 8(3):173.
18.Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, NasriF, et al. Effect of probiotic and synbiotic supplementation oninflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2020; 39(3): 789-819.
19. Samimi M, Dadkhah A, Haddad Kashani H, Tajabadi-Ebrahimi M, Seyed Hosseini E, Asemi Z. The effects of symbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics Antimicrob Proteins. 2019; 11(4): 1355-1361.
20. Karimi E, Moini A, Yaseri M, Shirzad N, Sepidarkish M, Hossein- Boroujerdi M, et al. Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial. Br J Nutr. 2018; 119(4): 398-406.
21. Nasri K, Jamilian M, Rahmani E, Bahmani F, Tajabadi-Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord. 2018; 18(1): 21.
22. Lindheim L, Bashir M, Münzker J, Trummer C, Zachhuber V, Leber B, et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS One. 2017; 12(1): e0168390.
23. Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017; 20(4): 254-261.
24. Olszanecka-Glinianowicz M, Madej P, Nylec M, Owczarek A, Szanecki W, Skałba P, et al. Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances. Clin Endocrinol (Oxf). 2013; 79(2): 238-242.
25. Sanda B, Vistad I, Haakstad LAH, Berntsen S, Sagedal LR, Lohne- Seiler H, et al. Reliability and concurrent validity of the International Physical Activity Questionnaire short form among pregnant women. BMC Sports Sci Med Rehabil. 2017; 9: 7.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-419.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499-502.
28. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016; 8(1): 42.
29. Esmaeilinezhad Z, Babajafari S, Sohrabi Z, Eskandari MH, Amooee S, Barati-Boldaji R. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial. Nutr Metab Cardiovasc Dis. 2019; 29(2): 201-208.
30. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012; 57(2): 545-553.
31. Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial. Diabetes Metab Syndr. 2019; 13(1): 175-182.
32. Hosseini-Esfahani F, Bahadoran Z, Moslehi N, Asghari G, Yuzbashian E, Hosseinpour-Niazi S, et al. Metabolic syndrome: findings from 20 years of the tehran lipid and glucose study. Int J Endocrinol Metab. 2018; 16(4 Suppl): e84771.
33. Roselino MN, Pauly-Silveira ND, Cavallini DC, Celiberto LS, Pinto RA, Vendramini RC, et al. A potential synbiotic product improves the lipid profile of diabetic rats. Lipids Health Dis. 2012; 11: 114.
34. Liong MT, Shah NP. Effects of a Lactobacillus casei synbiotic on serum lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci. 2006; 89(5): 1390-1399.
35. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016; 7: 124.
36. Cerdó T, García-Santos JA, G Bermúdez M, Campoy C. The role of probiotics and prebiotics in the prevention and treatment of obesity. Nutrients. 2019; 11(3): 635.
37. Bala M, Meenakshi, K M, Gupta A. Correlation of HbA1C levels with body mass index in newly diagnosed polycystic ovary syndrome. EJIFCC. 2017; 28(3): 196-204.
38. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014; 5(1): 3-17.
39. Altinkaya SÖ, Nergiz S, Küçük M, Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 176: 168-172.